Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines

Autor: Joan G. Meeder, Matthijs Versteegh, Maureen P.M.H. Rutten-van Mölken, Rudolf A. de Boer, Gerard C.M. Linssen, Jolanda M.A. Koenders, Isaac Corro Ramos
Přispěvatelé: Cardiovascular Centre (CVC), Health Technology Assessment (HTA)
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Cost effectiveness
Cost-Benefit Analysis
productivity costs
Tetrazoles
heart failure
Angiotensin-Converting Enzyme Inhibitors
Expected value of perfect information
UNCERTAINTY
030204 cardiovascular system & hematology
DECISION-MAKING
ECONOMIC-EVALUATION
0302 clinical medicine
Netherlands
Randomized Controlled Trials as Topic
education.field_of_study
Aminobutyrates
030503 health policy & services
Health Policy
cost-effectiveness analysis
Cost-effectiveness analysis
EFFECTIVENESS MODELS
Middle Aged
Drug Combinations
Models
Economic
HEALTH-CARE TECHNOLOGIES
ENALAPRIL
Valsartan
Female
Neprilysin
Quality-Adjusted Life Years
0305 other medical science
medicine.drug
medicine.medical_specialty
Population
Guidelines as Topic
Angiotensin Receptor Antagonists
03 medical and health sciences
ASSOCIATION CLASSES
ACE inhibitor
medicine
Humans
SENSITIVITY ANALYSIS
Economics
Pharmaceutical
Enalapril
Intensive care medicine
education
Aged
business.industry
MORTALITY
Biphenyl Compounds
Public Health
Environmental and Occupational Health
Stroke Volume
Chronic Disease
Economic evaluation
INFORMATION ANALYSIS
business
Sacubitril
Valsartan
Zdroj: Value in Health, 20(10), 1260-1269. ELSEVIER SCIENCE INC
Value in Health. Elsevier Ltd.
ISSN: 1098-3015
Popis: Objectives: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in adult patients with chronic heart failure with reduced left ventricular ejection fraction in the Netherlands; and to explore the effect of performing the cost-effectiveness analyses according to the new pharmacoeconomic Dutch guidelines (updated during the submission process of LCZ696), which require a value-of-information analysis and the inclusion of indirect medical costs of life-years gained.Methods: We adapted a UK model to reflect the societal perspective in the Netherlands by including travel expenses, productivity loss, informal care costs, and indirect medical costs during the life-years gained and performed a preliminary value-of-information analysis.Results: The incremental cost-effectiveness ratio obtained was (sic)17,600 per quality-adjusted life-year (QALY) gained. This was robust to changes in most structural assumptions and across different subgroups of patients. Probability sensitivity analysis results showed that the probability that LCZ696 is cost-effective at a (sic)50,000 per QALY threshold is 99.8%, with a population expected value of perfect information of (sic)297,128. On including indirect medical costs of life-years gained, the incremental cost-effectiveness ratio was (sic)26,491 per QALY gained, and LCZ696 was 99.46% cost effective at (sic)50,000 per QALY, with a population expected value of perfect information of (sic)2,849,647.Conclusions: LCZ696 is cost effective compared with enalapril under the former and current Dutch guidelines. However, the (monetary) consequences of making a wrong decision were considerably different in both scenarios. Copyright (C) 2017, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.
Databáze: OpenAIRE
Externí odkaz: